Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00198081 · ClinicalTrials.gov registry record · Phase 2
Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)
A Phase 2 study, sponsored by Indiana University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00198081 is a Phase 2 study that was terminated before completion, run by Indiana University. The registered enrollment target is 8 participants.
The verdict
NCT00198081, a Phase 2 study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of the study is to find out whether the drug celecoxib has beneficial effects on people with pre-cancerous lesions of the pancreas.
Interventions
- DRUG COX-2 Inhibitor 6-8 weeks prior to surgery
- DRUG COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2005-09 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00198081
The ClinicalTrials.gov registry entry for NCT00198081 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which COX-2 Inhibitor 6-8 weeks prior to surgery is the first listed.
NCT00198081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00198081 about?
NCT00198081 is a clinical study titled "Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)". The purpose of the study is to find out whether the drug celecoxib has beneficial effects on people with pre-cancerous lesions of the pancreas.
What is the current status of trial NCT00198081?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2005-09. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00198081?
The interventions under investigation include: COX-2 Inhibitor 6-8 weeks prior to surgery (DRUG), COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP (DRUG).
Who is sponsoring clinical trial NCT00198081?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.